Background The phase 3 randomized PERSIST study demonstrated the efficacy and
tolerability of galcanezumab, a humanized anti-calcitonin gene-related peptide (CGRP) …

Background Galcanezumab has shown efficacy and effectiveness in the treatment of
episodic and chronic migraine (CM), however, the population represented in randomized …

Objective To characterize adult patients with episodic migraine who achieved 100%
response to galcanezumab treatment. Background Galcanezumab is a humanized …

Background Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-
related peptide, has demonstrated efficacy and good tolerability in patients with episodic …

Background Galcanezumab, a monoclonal antibody to calcitonin gene-related peptide, was
found to be safe and efficacious for the preventive treatment of chronic migraine based on …

Background Safety findings from a Phase 2b study of galcanezumab, a humanized
monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine …

Background Galcanezumab, a humanized monoclonal antibody that selectively binds to the
calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical …

Objective To evaluate onset of effect of galcanezumab in patients with episodic migraine.
Background Galcanezumab is a monoclonal antibody that binds to calcitonin gene‐related …

Background Patients with high-frequency episodic migraine (HFEM) have a greater disease
burden than those with low-frequency episodic migraine (LFEM). Acute treatment overuse …

Introduction The consistency of the treatment effect of galcanezumab throughout the dosing
interval is examined in patients with episodic and chronic migraine. Methods This study was …